Xtherapeutics ApS: Financial statements 2023
CVR: 37384089
Source: annual report 2023, Danish Business Authority
01/07/2022 – 30/06/2023
Xtherapeutics ApS (CVR 37384089) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -17,083 and a net result of DKK -17,084 compared with DKK -14,381 the year before. Equity in the 2023 report amounted to DKK -4,116.
- Gross Profit
- DKK -17,083
- Profit/Loss
- DKK -17,084
- Equity
- DKK -4,116
- Total Assets
- DKK 13,771
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -17 t. | -17 t. | -4 t. | - |
| 2022 | - | -9 t. | -14 t. | 13 t. | - |
| 2021 | - | - | -5 t. | -13 t. | - |
| 2020 | 0 | 0 | 0 | 1 | - |
| 2019 | 0 | 0 | 0 | 1 | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationAbout Xtherapeutics ApS
Xtherapeutics ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Xtherapeutics IVS and Vaccex IVS. The management consists of Thomas Lars Andresen. The company is owned by Jonas Rosager Henriksen, Anders Elias Hansen and TLA-HOLDING 2010 ApS. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK 0 compared with DKK -14,323 the year before. Equity in the 2025 report amounted to DKK -18,439.